facebook pixel code
image of colored blocks

PAVING THE
WAY FOR FUTURE
GENERATIONS

If you or a loved one has been diagnosed with Alzheimer's disease, or a physician suspects it may be Alzheimer's disease, you or they may be eligible to participate in a clinical research study to help advance the treatment of Alzheimer’s.

Complete the Pre-Screener
RethinkALZ and RefocusALZ Clinical Research Studies

RethinkALZ and RefocusALZ Clinical Research Studies

The rethinkALZ and refocusALZ clinical research studies are currently enrolling patients. The purpose of these research studies is to learn more about the use of the study drug, simufilam, for the treatment of mild-to-moderate Alzheimer's disease. We want to test that it is safe and find out whether it can slow down disease progression and improve thinking and memory in people with Alzheimer’s disease.

To be considered for the rethinkALZ or refocusALZ study, patients must:

  • Be ages 50 to 87 years old
  • Be diagnosed with, or have a suspected clinical diagnosis of, Alzheimer's disease
  • Have a gradual change in memory for six months or more
  • Have a family member or loved one who can be available as a study partner during the entire study
  • Be fully vaccinated for COVID-19 or have had a previous COVID-19 infection

Other criteria will apply.

Learn More About the Studies

Interested in participating?

See if you or your loved one would be eligible to participate in either the rethinkALZ or refocusALZ clinical research studies.

Complete the Pre-Screener

Refer A Friend

Do you know a family member or loved one who is diagnosed with Alzheimer’s disease? They may be eligible to participate in either the rethinkALZ or refocusALZ clinical research studies. Consider sharing information with them about how they can learn more.

Share this Study